- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04416750
Positioning Imatinib for Pulmonary Arterial Hypertension (PIPAH)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
What does the study involve?
The study involves treatment of PAH patients with imatinib (study drug) for up to 24 weeks, and clinical assessments and tests to assess the drug's safety and tolerability.
PAH patients will be seen at their local hospital by the PAH clinical research team. Before someone can start study, the study doctor (or clinical study team) will describe the clinical trial in detail. If a potential subject decides to participate, he/she will be asked to sign the informed consent form before any study procedures are done.
Participants will be asked to come to their local hospital for clinical appointments. This includes a screening visit, a baseline visit, three clinical assessments and an end-of-study visit. In between, and at the very end of these, there will be six tele-visits (assessments over the phone). Each clinical appointment will be on a weekday morning or afternoon. No major lifestyle restrictions are required for these appointments.
Participants will undergo clinical examinations and tests to monitor the severity of PAH and the response to the study drug. Clinical procedures include:
- Questions about demographics, medical and medication history
- Physical examination and record of vital signs (blood pressure, temperature, heart and respiratory rate)
- Questionnaire about quality of life,
- Assessments of PAH severity (WHO Functional Class, six-minute walk test, and Borg dyspnoea index)
- Right heart catheterisation to assess response to the drug
- Haematology and clinical chemistry blood tests to ensure safety
- Serum pregnancy test and urine pregnancy tests (if applicable) to exclude pregnancy
- Blood samples to measure the levels of the study drug in the circulation
- Additional blood samples for future research on PAH and/or the mechanism of action of the drug
- Electrocardiogram (ECG), and echocardiogram to assess the size, shape, pumping action and the extent of any damage to the heart
- Brain MRI scan (or CT scan if MR is not indicated/tolerated) to exclude bleeding in the brain
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Cambridge, United Kingdom, CB2 0AY
- Royal Papworth Hospital, Royal Papworth Hospital NHS Foundation Trust
-
London, United Kingdom, SW3 6NP
- Royal Brompton Hospital, Royal Brompton & Harefield NHS Foundation Trust
-
Sheffield, United Kingdom, S10 2JF
- Royal Hallamshire Hospital, Sheffield Teaching Hospitals NHS Foundation
-
-
Greater London
-
London, Greater London, United Kingdom, W12 0HS
- Hammersmith Hospital, Imperial College Healthcare NHS Trust
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Subjects aged between 18-80 years old
- PAH which is idiopathic; PAH heritable; PAH associated with connective tissue disease; PAH after ≥ 1 year repair of congenital systemic to pulmonary shunt, or PAH associated with anorexigens or other drugs
- Subjects willing to be genotyped for genes that influence PDGF activity
- Resting mean pulmonary artery pressure ≥25 mmHg, Pulmonary capillary wedge pressure ≤15 mmHg, PVR >5 wood units, and normal or reduced cardiac output , as measured by right heart catheterisation (RHC) at entry
- Six-minute walking distance >50m at entry
- Stable on an unchanged PAH therapeutic regime comprising at least 2 therapies licensed for PAH (any combination of endothelin receptor antagonist, phosphodiesterase inhibitor or prostacyclin analogue) for at least 1 month prior to screening
- Able to provide written informed consent prior to any study mandated procedures
- Contraception: Fertile females (women of childbearing potential) are eligible to participate after a negative highly sensitive pregnancy test, if they are taking a highly effective method of contraception during treatment and until the end of relevant systemic exposure. Fertile males who make use of condom and contraception methods during treatment and until the end of relevant systemic exposure in women of childbearing potential -full details are in included in the research protocol-
Exclusion criteria:
- Unable to provide informed consent and/or are non-fluent speakers of the English language
- Hypersensitivity to Imatinib or to any of the excipients
- Clinically-significant renal disease (confirmed by creatinine clearance <30 ml/min per 1.73m2)
- Clinically-significant liver disease (confirmed by serum transaminases >3 times than upper normal limit)
- Patients receiving oral and/or parenteral anticoagulants (this does not apply to single antiplatelet therapy)
- Anaemia confirmed by haemoglobin concentration <10 g/dl
- History of thrombocytopenia
- Individuals known to have haemoglobinopathy sickle cell disease, thalassaemia
- Hospital admission related to PAH or change in PAH therapy within 3 months prior to screening
History of left-sided heart disease and/or clinically significant cardiac disease, including but not limited to any of the following:
- Aortic or mitral valve disease (stenosis or regurgitation) defined as greater than mild aortic insufficiency, mild aortic stenosis, mild mitral stenosis, moderate mitral regurgitation
- Mechanical or bioprosthetic cardiac valve
- Pericardial constriction, effusion with tamponade physiology, or abnormal left atrial size.
- Restrictive or congestive cardiomyopathy
- Left ventricular ejection fraction ≤50% (measured in echocardiogram at screening)
- Symptomatic coronary disease
- Significant (2+ for regurgitation) valvular disease other than tricuspid or pulmonary regurgitation
- Acutely decompensated left heart failure within 1 month of screening
- History of untreated obstructive sleep apnoea
- Evidence of significant lung disease on high-resolution CT (if available) or recent (performed within 12 months) lung function, where FEV1 < 50% predicted and FVC < 70% predicted, and DLCO (or TLCO) < 50% predicted if any CT abnormalities; judged by the Site Physician
- Patients with a history of uncontrolled systemic hypertension
- Acute infection (including eye, dental, and skin infections)
- Chronic inflammatory disease including HIV, and Hepatitis B
- Women of childbearing potential who are pregnant or breastfeeding (if applicable)
- Previous intracerebral haemorrhage
- Patients who have received an Investigational Medicinal Product (IMP) within 5 half-lives of the last dose of the IMP or 1 month (whichever is greater) before the baseline visit
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment
Open label; Imatinib tablets administered once daily; Dosage: in the range of 100mg-400mg; Group evaluated: adults with PAH
|
Treatment with Imatinib
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Identifying the highest tolerated dose
Time Frame: 12 months
|
Part 1: Discontinuation of the drug for more than 5 consecutive days due to Grade 2 or above Adverse Events, defined by NCI criteria (version 5.0, 2017) adapted for the study.
|
12 months
|
Change in pulmonary vascular resistance (PVR)
Time Frame: 24 months
|
Part 2: The primary efficacy endpoint is a binary variable.
For patients with a baseline pulmonary vascular resistance (PVR) >1000 dynes·s·cm-5, success is defined by an absolute reduction in PVR of ≥300 dynes·s·cm-5 at 24 weeks.
For patients with a baseline PVR ≤1000 dynes·s·cm-5, success is a 30% reduction in PVR at 24 weeks.
|
24 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in exercise test
Time Frame: 24 weeks
|
Change in six minute walk distance (6MWD) at 24 weeks.
|
24 weeks
|
Change in ejection fraction measures
Time Frame: 24 weeks
|
Change in right ventricular ejection fraction (RVEF) values, measured in echocardiogram (at screening visit and at 24 weeks).
|
24 weeks
|
Change in brain natriuretic peptide (BNP) values
Time Frame: 24 weeks
|
Change in plasma BNP (or proNT-BNP) levels from baseline at 24 weeks.
|
24 weeks
|
Change in quality of life scores
Time Frame: 24 weeks
|
Change in Quality of Life (QoL) scores from baseline at 24 weeks.
|
24 weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Plasma proteome measures
Time Frame: 24 weeks
|
Change in plasma proteome from baseline at 24 weeks.
|
24 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Director: Martin R Wilkins, MD, FRCP, Imperial College London
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Respiratory Tract Diseases
- Lung Diseases
- Hypertension, Pulmonary
- Hypertension
- Pulmonary Arterial Hypertension
- Familial Primary Pulmonary Hypertension
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Protein Kinase Inhibitors
- Imatinib Mesylate
Other Study ID Numbers
- IRAS ID: 274093
- 2020-001157-48 (EudraCT Number)
- 20HH5896 (Other Identifier: Sponsor (Imperial College London))
- 20/SC/0240 (Other Identifier: Health Research Authority (UK))
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pulmonary Arterial Hypertension
-
Vanderbilt University Medical CenterJohns Hopkins UniversityCompletedPulmonary Arterial Hypertension | Idiopathic Pulmonary Arterial Hypertension | Associated Pulmonary Arterial Hypertension | Heritable Pulmonary Arterial HypertensionUnited States
-
American Medical Association FoundationWithdrawnIdiopathic Pulmonary Arterial Hypertension.United States
-
Vanderbilt University Medical CenterRecruitingIdiopathic Pulmonary Arterial Hypertension | Heritable Pulmonary Arterial Hypertension | Scleroderma Associated Pulmonary Arterial Hypertension | Appetite Suppressant Associate PAHUnited States
-
Amsterdam UMC, location VUmcZonMw: The Netherlands Organisation for Health Research and DevelopmentUnknown
-
Association de Recherche en Physiopathologie RespiratoireGlaxoSmithKline; Soladis; InterlisUnknownPulmonary Arterial Hypertension (PAH)France
-
Medical University of GrazLudwig Boltzmann Institute for Lung Vascular ResearchCompletedIdiopathic Pulmonary Arterial HypertensionAustria
-
Zhejiang UniversityCompletedIdiopathic Pulmonary Arterial HypertensionChina
-
Gachon University Gil Medical CenterChonbuk National University Hospital; Samsung Medical Center; Pusan National... and other collaboratorsUnknownPulmonary Arterial Hypertension | Idiopathic Pulmonary Arterial Hypertension | Deep Phenotyping | Heritable Pulmonary Arterial HypertensionKorea, Republic of
-
Zhejiang UniversityUnknownIdiopathic Pulmonary Arterial HypertensionChina
-
Regina Steringer-MascherbauerUnknownPulmonary Arterial Hypertension WHO Group IAustria
Clinical Trials on Imatinib Mesylate
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.CompletedChronic Myeloid LeukemiaChina
-
Institut BergoniéNovartisTerminatedLeukemia, Myeloid, Chronic-PhaseFrance
-
Scandinavian Sarcoma GroupCompleted
-
Sarit AssoulineNovartisRecruitingChronic Myeloid Leukemia | Chronic Myeloid Leukemia in Remission | Chronic Myeloid Leukemia, BCR/ABL-PositiveCanada
-
Novartis PharmaceuticalsCompletedProgressive Gastrointestinal Stromal TumorGermany
-
Novartis PharmaceuticalsCompletedLife Threatening Diseases
-
UNICANCERCompletedDesmoid TumorFrance
-
University Hospital, BordeauxNovartis; Ministry of Health, FranceCompletedScleroderma, Systemic | Scleroderma, LocalizedFrance
-
Maisonneuve-Rosemont HospitalHippocrate Research & DevelopmentUnknownGastrointestinal Stromal TumorsCanada